1. Home
  2. WOLF vs TYRA Comparison

WOLF vs TYRA Comparison

Compare WOLF & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

HOLD

Current Price

$60.38

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$35.49

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOLF
TYRA
Founded
1987
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
WOLF
TYRA
Price
$60.38
$35.49
Analyst Decision
Sell
Strong Buy
Analyst Count
4
11
Target Price
$14.33
$47.50
AVG Volume (30 Days)
8.5M
770.8K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,385,982,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$0.39
$8.75
52 Week High
$73.74
$40.65

Technical Indicators

Market Signals
Indicator
WOLF
TYRA
Relative Strength Index (RSI) 72.62 51.58
Support Level $15.86 $33.29
Resistance Level N/A $39.48
Average True Range (ATR) 7.55 2.08
MACD 2.40 0.25
Stochastic Oscillator 72.70 70.87

Price Performance

Historical Comparison
WOLF
TYRA

About WOLF Wolfspeed Inc.

Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: